DSO acquisitions dominate the larger end of the UK dental practice market. For practices with a material NHS contract, strong private revenue, or multiple surgeries, DSOs represent the most active buyer pool — and often the highest valuations. But a DSO deal is structurally different from a sale to a private individual, and sellers who go into the process without understanding the deal mechanics routinely receive less than the headline price suggests.
This guide covers what DSOs are actually acquiring and why that drives the deal structure, the earn-out mechanics standard in DSO transactions, what the transition period requires, how integration works in practice, staff implications, clinical autonomy, the tax position, and how to assess the total economic value of a DSO offer before you sign.
1. What a DSO Is Buying — and Why That Drives the Deal Structure
Understanding what a DSO acquires helps explain why the deal is structured the way it is.
A DSO is not buying a clinical space and a patient list. It is acquiring a revenue-generating business with a recurring income stream — one that it intends to absorb into its group clinical governance framework, run on its cost base, and grow. The value to the DSO is an EBITDA multiple: the sustainable annual earnings the practice produces, capitalised at the DSO’s acquisition multiple.
Because the DSO’s value depends on the practice continuing to perform after completion, and because continuation depends heavily on the clinical relationships and management the selling principal provides, DSOs routinely structure a portion of the price as deferred — payable only if the practice delivers against agreed performance targets during a post-completion period. This is the earn-out.
The earn-out is not a penalty or a sign of buyer caution. It is the mechanism by which the DSO aligns your incentive — to keep the practice performing — with its interest as the incoming owner. Understanding this logic helps you negotiate the structure rather than simply reacting to it.
2. The Earn-Out: Mechanics and Protections
Typical structure. In a DSO deal, 25–35% of the total consideration is typically deferred into an earn-out. The earn-out period runs for twelve to thirty-six months from completion. The performance measure is usually EBITDA — either absolute EBITDA against a target, or EBITDA as a percentage of revenue — or, for NHS practices, UDA delivery against contract target.
Non-interference provisions are critical. The earn-out EBITDA definition is the most important drafting issue in a DSO deal. Once the DSO owns the practice, it controls the cost base — staffing, supplies, lab fees, software subscriptions, and central overhead recharges. An earn-out calculated on reported group EBITDA — including DSO integration costs, central overhead allocations, or supplier cost increases imposed post-completion — can be eroded by buyer decisions that are commercially rational at group level but directly reduce what the seller earns.
Proper non-interference provisions must:
- Define EBITDA for earn-out purposes by reference to the practice’s cost structure at completion, excluding DSO-imposed integration costs
- Exclude central overhead recharges or allocations not present at the time of valuation
- Preserve the clinical team structure during the earn-out period — DSO-initiated staffing changes that reduce clinical capacity reduce EBITDA
- Require DSO consent for any significant cost increase during the earn-out not anticipated in the business plan at heads of terms
Without these protections, the earn-out is nominal. This is not a theoretical concern — DSO earn-out disputes frequently arise from exactly this dynamic. The non-interference provisions must be agreed and documented in heads of terms, not left to be negotiated during SPA drafting. By the time a DSO solicitor produces a draft SPA, you are negotiating within their template, and your leverage to insert earn-out protections from scratch is substantially lower.
3. The Transition Period: What You Are Actually Agreeing To
DSO deals almost universally require the selling principal to remain involved post-completion. The transition period in a DSO transaction is substantive — not a brief handover but a real ongoing clinical and operational obligation, typically running twelve to twenty-four months.
During the transition period, the principal will be expected to continue clinical sessions at agreed volumes; provide management continuity while the DSO integration team embeds; support patient communications introducing the new ownership; and in many cases participate in DSO clinical governance structures — peer review, clinical audits — in a leadership capacity.
Remuneration must be agreed at heads of terms. This is consistently left undefined. Sellers focus on the purchase price, and transition employment terms are deferred to “usual associate rates” or a later employment agreement. This is a mistake, for two reasons.
First, the principal’s remuneration during the earn-out period directly affects earn-out EBITDA. If the principal is remunerated below market rate, the earn-out EBITDA looks better but the principal has subsidised it. If remunerated at market rate, the earn-out target must reflect that cost. The numbers need to be modelled together.
Second, the clinical sessions obligation — the volume of chair time the principal must deliver — determines how much of their time and earning capacity is committed to the earn-out practice. A twelve-month earn-out requiring four days a week of clinical sessions at below-market remuneration is a materially different obligation to one requiring two days a week at full associate rates.
Lock in remuneration and sessions obligation at HoT stage.
4. Integration: Clinical Governance, Branding, and Systems
When a DSO acquires a practice, it integrates it into its group structure. Understanding what this means in practice matters for both the transition period and ongoing clinical work.
Clinical governance absorbs into the DSO’s group-level framework. CQC registration shifts to the DSO entity or its governance structure; group-level policies replace practice-specific policies; peer review and clinical audit operate at group level. For the transitioning principal, this reduces direct regulatory burden — the DSO holds the compliance framework — but it means loss of control over how clinical quality is managed day-to-day.
Branding. DSOs typically rebrand acquired practices at some point post-completion. Timing varies: some rebrand immediately, others retain the practice name through the earn-out period before phasing to the group brand. Immediate rebranding can affect patient retention and therefore earn-out EBITDA. Push for the branding timeline to be agreed at HoT stage, and if patient retention risk is material, ensure the non-interference provisions address it.
PMS migration. The DSO will migrate the practice to its group practice management system. This transition carries operational risk — data migration, staff retraining, and short-term booking disruption. A PMS migration in month three of a twelve-month earn-out creates a direct EBITDA exposure. The migration timeline should be reviewed in the context of the earn-out period and, where the risk is significant, phased to protect earn-out performance.
5. Staff and TUPE
TUPE applies on an asset sale; on a share sale the employment contracts transfer with the company. Either way, staff transfer with their existing terms and conditions, and those terms are protected.
Staff retention is material to earn-out performance. Key associates, the hygienist, and experienced reception staff departing during the earn-out period will underperform against the EBITDA target. DSOs understand this — and in better-negotiated deals, the DSO carries obligations on staff retention, not only the seller.
Negotiate staff retention as part of the non-interference provisions: the DSO should not restructure or issue new employment contracts to key clinical staff during the earn-out period without seller consent. Any DSO-initiated departures — restructures, changes in terms that drive a resignation — should be excluded from the earn-out EBITDA calculation for the period of their effect.
6. Clinical Autonomy
Clinical autonomy — the principal’s right to make clinical decisions without DSO interference — is the most important non-financial term in a DSO deal. For most principals, freedom from corporate override of individual clinical decisions is a dealbreaker if it is not protected.
The most productive time to negotiate clinical autonomy is at heads of terms. By SPA stage, the DSO legal team is drafting from a template that rarely includes robust clinical autonomy provisions, and there is limited leverage to insert them.
Minimum clinical autonomy protections should cover: freedom from DSO override of individual treatment decisions; the right to prescribe treatment in line with the principal’s clinical judgement rather than DSO protocols; and explicit protection against any requirement that would place the principal’s GDC registration at risk.
7. Tax: BADR and the Earn-Out Problem
The tax position on a DSO deal carries a specific complexity not present in a straightforward individual buyer transaction: the earn-out right.
The starting analysis — asset sale versus share sale — applies in the same way as any other dental practice sale. For incorporated practices, a qualifying share sale with Business Asset Disposal Relief reduces CGT to 18% (from April 2026) on the first £1 million of qualifying lifetime gains, against an effective 50%+ combined rate on an asset sale via corporation tax and dividend extraction. BADR eligibility and structure should be confirmed before any DSO offer is accepted.
However, in a DSO deal with an earn-out, there is an additional layer: the Marren v Ingles (1980) analysis. When the right to receive a future earn-out is created at completion, that right is itself a capital asset, valued at the date of disposal. Under HMRC practice, BADR applies to the gain on the whole disposal at completion — including the deemed value of the earn-out right. CGT at the BADR rate is due on that deemed value in the year of completion, before the earn-out cash is received.
When earn-out receipts are subsequently paid, they are treated as proceeds from the disposal of the earn-out right and taxed at the standard CGT rate at the time of receipt — not the BADR rate.
This creates a liquidity issue. If the earn-out right is valued at £350,000 at completion, CGT may be due on that amount in year one — before a penny of earn-out cash has been received. Sellers must model this with their accountant and ensure that sufficient cash from the upfront tranche covers the CGT liability on the earn-out right at completion.
8. Evaluating a DSO Offer: Total Economic Value
A DSO offer must be assessed on total economic value, not headline price. The calculation is:
Upfront price + earn-out at a realistic discounted value − CGT on the earn-out right at completion − subsequent CGT on earn-out receipts − cost of obligations required to earn the earn-out = net economic value
The cost of obligations includes: remuneration during the transition period (if below market, this is a hidden reduction to net value); clinical sessions volume (the opportunity cost of those days versus locum or other work); and the operational contribution to DSO integration.
When comparing DSO offers, model each offer on this basis. An offer with a higher headline but a larger earn-out fraction, weak non-interference protections, below-market transition remuneration, and aggressive EBITDA targets may deliver materially less than an offer with a lower headline and a higher upfront proportion with robust earn-out protections.
For a complete guide to the sale process, see how to sell your dental practice.
Get a free confidential dental practice valuation →
Frequently Asked Questions
What percentage of the sale price is typically deferred in a DSO deal?
Most DSO deals defer 25–35% of the total consideration into an earn-out, payable over twelve to thirty-six months from completion. The earn-out is performance-linked — typically EBITDA or UDA delivery — and requires the selling principal to remain involved clinically and operationally during the earn-out period.
What is a non-interference clause in a DSO earn-out?
A non-interference clause protects the seller’s ability to earn the earn-out by limiting the DSO’s right to impose cost changes, restructure clinical teams, or alter the cost base during the earn-out period. Without non-interference protections, the DSO controls the EBITDA calculation and can legally erode the earn-out through post-completion cost decisions. These protections must be agreed at heads of terms, before the DSO’s SPA template is in play.
How does BADR apply when selling to a DSO with an earn-out?
Under Marren v Ingles, the right to receive an earn-out is itself a capital asset valued at completion. BADR applies to the gain on the full disposal — including the deemed value of the earn-out right — in the year of completion, before earn-out cash is received. Earn-out receipts paid in later years are then taxed as proceeds from disposal of the earn-out right at the standard CGT rate. Sellers must hold sufficient upfront cash to fund the CGT liability on the earn-out right in year one.
Can I negotiate clinical autonomy when selling to a DSO?
Yes, but it must be negotiated at heads of terms stage. By the time the SPA is being drafted, the DSO’s legal template will rarely include clinical autonomy provisions and there is limited leverage to insert them without agreed HoT protections. A minimum clinical autonomy provision covers freedom from DSO override of individual clinical decisions and protection against any requirement that would place the principal’s GDC registration at risk.
What happens to my staff when I sell to a DSO?
TUPE applies. Staff transfer with their existing terms and employment continuity protected. For the earn-out, staff retention is material — key clinical and reception staff departing during the earn-out period directly reduces EBITDA. Sellers should negotiate staff retention obligations on the DSO as part of the non-interference provisions, with DSO-initiated departures excluded from earn-out EBITDA for the period of their effect.